Ocrelizumab Lowers Patient Risk of Upper Extremity Disability in PPMS


New study finds that ocrelizumab (Ocrevus) has the capability to reduce risk of upper extremity disability progression in patients with primary progressive multiple sclerosis (PPMS).

A new assessment of ocrelizumab (Ocrevus) in patients with primary progressive multiple sclerosis (PPMS)

has found the monoclonal antibody has capability to reduce patient risk of upper extremity (UE) disability progression.

In new findings from the phase 3 randomized ORATORIO trial, investigators analyzed ocrelizumab versus placebo in an intent-to-treat patient population stratified by Nine-Hole Peg Test (9HPT) and Expanded Disability Status Scale (EDSS) scores at baseline. Assessing for reduced risk of disability progression remains a focal point for progressing MS care.

Led by Edward J. Fox, MD, of Penn State Health, the team emphasized how the rare MS

subtype PPMS is characterized by the gradual debilitation of patient neurological ability that could affect their everyday motor, sensory, coordination, and cognitive function.

UE impairment impacts patients’ ability to perform activities of daily living, affecting their independence and quality of life,” investigators wrote. “Moreover, the association of UE dysfunction and unemployment in patients with MS highlights the economic impact of compromised hand/arm function in MS.”

Ocrelizumab, from Genentech, was first approved by the US Food and Drug Administration (FDA) for the treatment of relapsing-remitting MS (RRMS) and PPPMS in March 2017—making history as the first therapy indicated for the latter MS subtype. Its approval was partially based on previous results to come from the ORATORIO trial series.

In using the EDSS and 9HPT scales as a metric for the therapy’s influence on disability risk reduction, the investigators were additionally providing context to ocrelizumab’s benefits for ambulation rates and MS-related costs, as both tests provide context to either facet. A clinically meaningful change in 9HPT time is commonly defined as an increase of ≥20%.

Continue reading on MD Magazine.

Related Videos
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.